Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy (HAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02996409
Recruitment Status : Completed
First Posted : December 19, 2016
Last Update Posted : August 15, 2019
Sponsor:
Collaborators:
Dutch Arthritis Association
The Anna Foundation
Information provided by (Responsible Party):
A.C. van der Vlist, Erasmus Medical Center

Brief Summary:
Overuse injury of the Achilles tendon is a common entity in athletes. Currently, the usual treatment for chronic midportion Achilles tendinopathy is an eccentric exercise program. In most cases this gives satisfactory results, however there is a significant group of patients in which the exercise program is not sufficient. Prior to our study, three United Kingdom based studies have investigated the efficacy of High-Volume Image-Guided Injections (HVIGI's) in chronic midportion Achilles tendinopathy. They all showed promising results. However none of these studies had an adequate control group. This double-blind, placebo-controlled, randomized clinical trial will investigate the value of a High-Volume Image-Guided Injection in chronic midportion Achilles tendinopathy.

Condition or disease Intervention/treatment Phase
Tendinopathy Achilles Tendon Pain Injection Site Fibrosis Drug: HVIGI Drug: LVIGI Other: Progressive exercise program Phase 4

Detailed Description:

Background of the study - Overuse injury of the Achilles tendon is a common entity in athletes. Especially middle aged athletes are at risk. Elite running athletes have a lifetime risk of sustaining an Achilles tendon injury of 52%. At the moment the usual treatment for chronic midportion Achilles tendinopathy is an excentric exercise program. In most cases this gives great results, however there is a significant group of patients in which the exercise program is not sufficient. Three United Kingdom-based case series evaluated the efficacy of High-Volume Image-Guided Injections (HVIGI's) in chronic midportion Achilles tendinopathy. They all showed promising results. However none of these studies used a comparative group. There is consequently a lack of high-quality studies in this field and therefore the investigators cannot recommend this treatment yet for this indication.

Objective of the study - To investigate the efficacy of a high-volume image guided injection (HVIGI) in chronic midportion Achilles tendinopathy.

Hypothesis - The average VISA-A score is higher in the patient group treated with a progressive exercise program in combination with a high volume image guided injection in comparison with the group treated with low volume injection as a control group in combination with a progressive exercise program.

Study design - A double-blind, randomized, placebo-controlled clinical trial. Randomization and stratification (based on activity level using the Ankle Activity Score) will be performed using a computer-generated model. Measurements will be performed at baseline, 2, 6, 12 and 24 weeks post injection. At every time point both the primary and secondary outcome measurements will be collected. The painDETECT and the Pain Coping Inventory questionnaires will be derived at baseline and 24 week post injection.

Study population - In total, 80 patients with clinically diagnosed chronic midportion Achilles tendinopathy will be included in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Value of a High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy: a Double-blind, Randomized, Placebo-controlled Clinical Trial
Actual Study Start Date : December 2016
Actual Primary Completion Date : July 2019
Actual Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tendinitis
Drug Information available for: Lidocaine

Arm Intervention/treatment
Experimental: High-Volume Image-Guided Injection
HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
Drug: HVIGI
High Volume Image-Guided Injection with a saline/lidocain solution
Other Names:
  • Saline 0.9% 40 ml
  • Lidocain 1.0% 10 ml

Other: Progressive exercise program
A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.

Placebo Comparator: Low-Volume Image-Guided Injection
LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
Drug: LVIGI
Placebo control with injection of a saline/lidocain solution (low volume)
Other Names:
  • Saline 0.9% 1.6 ml
  • Lidocain 1.0% 0.4 ml

Other: Progressive exercise program
A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.




Primary Outcome Measures :
  1. Victorian Institute of Sport Assessment - Achilles questionnaire (VISA-A) [ Time Frame: Change in VISA-A score at 24 weeks ]

Secondary Outcome Measures :
  1. Pain detect questionnaire (PD-Q) [ Time Frame: Change in pain detect score at 24 weeks ]
  2. The Pain Coping Inventory (PCI) [ Time Frame: Change in PCI score at 24 weeks ]
  3. 10 hop test [ Time Frame: Change in visual analogue scale score following a 10 hop test at 24 weeks ]
  4. Flexibility m. gastrocnemius using a goniometer [ Time Frame: Change in flexibility of the gastrocnemius muscle at 24 weeks ]
  5. Flexibility m. soleus using a goniometer [ Time Frame: Change in flexibility of the soleus muscle at 24 weeks ]
  6. Power m. gastrocnemius using a hand-held dynamometer [ Time Frame: Change in power of the gastrocnemius muscle at 24 weeks ]
  7. Power m. soleus using a hand-held dynamometer [ Time Frame: Change in power of the soleus muscle at 24 weeks ]
  8. Degree of neovascularisation (determined with standardized Power Doppler Ultrasonography examination) [ Time Frame: Change in degree of neovascularization at 24 weeks ]
    Ultrasonography examination before and after eccentric/isotonic calf exercises or rest

  9. Return to sports using a standardized weekly questionnaire [ Time Frame: Change in return to sport at 24 weeks ]
  10. Compliance to the exercise program and return to sports activity program using a standardized weekly questionnaire assessing the percentage of exercises that is performed [ Time Frame: Change in compliance at 24 weeks ]
  11. Patient satisfaction with treatment results [ Time Frame: Change at 24 weeks ]
  12. Patient Acceptable Symptom Scale (PASS) [ Time Frame: Change at 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-70 years.
  2. Clinical diagnosis of chronic midportion Achilles tendinopathy: Painful swelling of the Achilles tendon, 2-7 cm proximal to it's calcaneal insertion.
  3. Non-response to exercise program for 6 weeks.
  4. Painful Achilles tendon for more than 2 months.
  5. Neovascularisation is present on Power Doppler Ultrasonography examination

Exclusion Criteria:

  1. Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum)
  2. Clinical suspicion of an Achilles tendon rupture (Thompson test abnormal and palpable "gap")
  3. Clinical suspicion of plantar flexor tenosynovitis (posteromedial pain when the toes are plantar flexed against resistance)
  4. Clinical suspicion of n.suralis pathology (sensitive disorder in the area of the sural nerve)
  5. Clinical suspicion of peroneal subluxation (visible luxation of the mm. Peronea spot in combination with localized pain)
  6. Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.
  7. Condition that prevents the patients from executing an active exercise program
  8. Recently prescribed drugs (within 2 years) with a putative effect on symptoms and tendon healing (quinolone antibiotics, corticosteroids).
  9. Previous Achilles tendon rupture.
  10. Patient has received surgical intervention for his injury.
  11. Patient does not wish, for whatever reason, to undergo one of the two treatments
  12. A medical condition that would affect safety of injection (e.g. peripheral vascular disease, use of anticoagulant medication)
  13. Known presence of a pregnancy
  14. Condition of the Achilles tendon caused by medications (arising in relation to moment of intake), such as quinolones and statins
  15. Inability to give informed consent.
  16. Participation in other concomitant treatment programs.
  17. Patient has already one side included in this study.
  18. Allergy for lidocain.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02996409


Locations
Layout table for location information
Netherlands
Erasmus MC University Medical Center
Rotterdam, Netherlands
Sponsors and Collaborators
Erasmus Medical Center
Dutch Arthritis Association
The Anna Foundation
Investigators
Layout table for investigator information
Principal Investigator: R.J. de Vos, PhD Erasmus MC University Medical Center
  Study Documents (Full-Text)

Documents provided by A.C. van der Vlist, Erasmus Medical Center:
Statistical Analysis Plan  [PDF] August 13, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: A.C. van der Vlist, Principal investigator, Erasmus Medical Center
ClinicalTrials.gov Identifier: NCT02996409    
Other Study ID Numbers: 51623
First Posted: December 19, 2016    Key Record Dates
Last Update Posted: August 15, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Tendon Injuries
Wounds and Injuries
Lidocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action